Table 1 Baseline characteristics of the study population
Chemotherapy (N = 31) | Best supportive care (N = 28) | p-value | |
|---|---|---|---|
Age | 78.0 [76.5–80.0] | 80.5 [77.0–84.3] | 0.118 |
Gender (male/female) | 4 / 27 | 4 / 24 | 1.00 |
ECOG Performance Status (2/3/4) | 18/12/1 | 8/15/5 | 0.0350 |
Smoking history | 30 (96.8%) | 22 (78.6%) | 0.0870 |
Brinkman Index | 1100 [780–1550] | 800 [420–1395] | 0.113 |
Comorbidities | |||
Emphysema (%) | 26 (83.9%) | 20 (71.4%) | 0.348 |
Interstitial pneumonia (%) | 1 (3.2%) | 1 (3.6%) | 1.00 |
Diabetes mellitus (%) | 13 (41.9%) | 1 (3.6%) | 0.00100 |
Histology (Non-Squamous/Squamous) | 6 / 25 | 6 / 22 | 1.00 |
Staging (IIB/IV) | 5 / 26 | 2 / 26 | 0.428 |
Major diameter of the primary site | 39.5 [27.5–65.0] | 52.0 [40.5–74.0] | 0.0740 |
Metastatic organ | |||
Brain (%) | 6 (19.4%) | 4 (14.3%) | 0.734 |
Bone (%) | 10 (32.3%) | 6 (21.4%) | 0.393 |
Liver (%) | 3 (9.7%) | 3 (10.7%) | 1.00 |
Adrenal gland (%) | 4 (12.9%) | 1 (3.6%) | 0.356 |
Laboratory data | |||
White blood cell count | 7800 [6450–9700] | 7700 [6175–11,925] | 0.802 |
Neutrophil count | 5336 [4502–6684] | 5988 [4513–8929] | 0.362 |
Lymphocyte count | 1396 [1148–1721] | 1086 [848–1432] | 0.0370 |
Hemoglobin | 12.4 [11.0–14.0] | 12.0 [11.5–13.2] | 0.885 |
Albumin | 3.60 [3.20–3.95] | 3.30 [2.85–3.62] | 0.0460 |
Lactate dehydrogenase | 214 [188–247] | 247 [206–277] | 0.141 |
Calcium | 9.20 [9.00–9.55] | 9.00 [8.47–9.33] | 0.093 |
C-reactive protein | 1.81 [0.66–3.92] | 3.20 [0.57–7.59] | 0.391 |